Virtu Financial LLC Purchases Shares of 20,988 REGENXBIO Inc. (NASDAQ:RGNX)

Virtu Financial LLC acquired a new position in REGENXBIO Inc. (NASDAQ:RGNX) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 20,988 shares of the biotechnology company’s stock, valued at approximately $377,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in REGENXBIO by 0.8% in the third quarter. Vanguard Group Inc. now owns 4,376,573 shares of the biotechnology company’s stock worth $72,038,000 after buying an additional 36,531 shares during the last quarter. Redmile Group LLC raised its position in shares of REGENXBIO by 27.0% during the third quarter. Redmile Group LLC now owns 2,574,042 shares of the biotechnology company’s stock worth $42,369,000 after purchasing an additional 547,466 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of REGENXBIO by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock valued at $22,025,000 after purchasing an additional 34,385 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of REGENXBIO by 0.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 562,391 shares of the biotechnology company’s stock valued at $9,257,000 after purchasing an additional 1,493 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in REGENXBIO in the 4th quarter worth about $6,146,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Buying and Selling

In other REGENXBIO news, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $15.81, for a total value of $237,150.00. Following the transaction, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at approximately $6,451,033.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 13.13% of the company’s stock.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $12.21 on Thursday. The firm has a market cap of $601.46 million, a price-to-earnings ratio of -2.08 and a beta of 1.34. The stock has a 50-day simple moving average of $15.33 and a 200-day simple moving average of $17.26. REGENXBIO Inc. has a 52-week low of $11.56 and a 52-week high of $28.80.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.10). REGENXBIO had a negative net margin of 299.96% and a negative return on equity of 70.72%. The business had revenue of $15.60 million during the quarter, compared to analyst estimates of $23.52 million. During the same quarter last year, the firm earned ($1.53) earnings per share. REGENXBIO’s revenue was down 18.3% compared to the same quarter last year. As a group, equities research analysts predict that REGENXBIO Inc. will post -3.9 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on RGNX. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Tuesday. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 7th. HC Wainwright lifted their price target on REGENXBIO from $36.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, May 15th. Raymond James reissued an “outperform” rating and issued a $45.00 price objective on shares of REGENXBIO in a research note on Wednesday, February 21st. Finally, Leerink Partnrs raised REGENXBIO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.58.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.